News
ALMS
9.04
-8.16%
-0.80
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 1d ago
Progress Software Posts Upbeat Results, Joins Microvast, PVH And Other Big Stocks Moving Higher On Tuesday
Benzinga · 2d ago
Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Benzinga · 2d ago
Weekly Report: what happened at ALMS last week (0324-0328)?
Weekly Report · 3d ago
Alumis Inc. Reports 2024 Results and Strategic Merger
TipRanks · 03/27 04:00
Strategic Partnerships and Financial Projections Bolster Buy Rating for Alumis Inc.
TipRanks · 03/26 10:26
Alumis, Kaken Pharmaceutical enter ESK-001 collaboration and licensing agreement
TipRanks · 03/25 19:09
What's Going On With Alumis Shares Tuesday?
Benzinga · 03/25 15:54
BUZZ-Alumis jumps on licensing deal for skin drug
Reuters · 03/25 15:25
Alumis Shares Rise on Licensing Agreement with Japanese Drug Company
Dow Jones · 03/25 15:12
ALUMIS SHARES UP 26.5% AFTER LICENSING AGREEMENT WITH KAKEN PHARMACEUTICAL
Reuters · 03/25 13:34
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 03/25 12:10
Alumis rises on licensing deal with Japan’s Kaken
Seeking Alpha · 03/25 10:53
Positive Buy Rating for Alumis Inc. Driven by Promising TYK2 Inhibitors and Strategic Advancements
TipRanks · 03/25 06:45
Alumis And Kaken Pharmaceutical Ink $40M Collaboration Deal For ESK-001 In Dermatology, With Potential $140M In Milestones
Benzinga · 03/25 06:45
Alumis And Kaken Pharma Partner To Advance ESK-001 TYK2 Inhibitor For Dermatology In Japan
NASDAQ · 03/25 06:41
ALUMIS INC - TO RECEIVE $40 MILLION UPFRONT, POTENTIAL $140 MILLION IN MILESTONE PAYMENTS
Reuters · 03/25 06:30
ALUMIS AND KAKEN PHARMACEUTICAL ANNOUNCE COLLABORATION AND LICENSING AGREEMENT FOR ESK-001 IN DERMATOLOGY IN JAPAN
Reuters · 03/25 06:30
Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan
Barchart · 03/25 01:30
Weekly Report: what happened at ALMS last week (0317-0321)?
Weekly Report · 03/24 12:30
More
Webull provides a variety of real-time ALMS stock news. You can receive the latest news about Alumis Inc through multiple platforms. This information may help you make smarter investment decisions.
About ALMS
More
Alumis Inc. is a clinical-stage biopharmaceutical company. It develops two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that it is developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. It builds a pipeline of molecules with the potential to address a range of immune-mediated diseases as monotherapy or combination therapies. ESK-001 is an allosteric TYK2 inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus and Uveitis. A-005 as a CNS-penetrant, allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a range of neuroinflammatory and neurodegenerative diseases. It has several early-stage discovery assets, such as targets identified by its data analytics platform, for the potential treatment of immune-mediated indications. Its data analytics demonstrate a genetic rationale for TYK2 inhibition in diseases of the CNS.